OT06 - Effect of Topical Glyceryl Glucoside on Clinical Signs and Skin Barrier in Canine Atopic Dermatitis

Abstract: Background - Canine atopic dermatitis (CAD) is characterized by impaired epidermal barrier function and reduced skin hydration. Glyceryl glucoside is an established humectant in human dermatology; however, its clinical efficacy in dogs has not been fully evaluated. Hypothesis/Objectives - We hypothesized that topical glyceryl glucoside would improve clinical signs and skin barrier function in dogs with CAD. Animals - Twenty dogs with naturally occurring CAD were randomized into three treatment groups. Methods - In this prospective, randomized, single-blinded, 8-week clinical trial, dogs received topical application of 3 % glyceryl glucoside plus 2 % panthenol (GP group, n = 7), glyceryl glucoside alone (G group, n = 7), or 3 % glycerin (control group, n = 6). Clinical severity and pruritus were assessed using CADESI-04 and pruritus visual analog scale (PVAS). Skin barrier function was evaluated using transepidermal water loss (TEWL) and stratum corneum hydration at baseline and weeks 4 and 8 . Results - At week 8, CADESI-04 scores were significantly reduced in the GP and G groups compared with the control group (p < 0.05). Percentage reductions in PVAS scores were greater in both treatment groups (p < 0.05). TEWL decreased and stratum corneum hydration increased significantly in the GP and G groups relative to controls (p < 0.05). The GP group showed significantly greater improvements than the G group (p < 0.01). Conclusion and Clinical importance - Topical glyceryl glucoside improved clinical severity, pruritus, and epidermal barrier function in dogs with CAD, supporting its use as an adjunctive therapy.